演題詳細

一般口演 / Oral Session

一般口演 5 (Oral Session 5) :移植後合併症

print

日程
2013年10月11日(金)
時間
09:30 - 10:30
会場
第5会場 / Room No.5 (さっぽろ芸文館 3F 清流)
座長・司会
谷口 修一 (Shuichi Taniguchi):1
1:虎の門病院 血液内科
 
前へ戻る

Early-phase elevated TNFα RI, sIL-2R, and LRG predict poor prognosis for allo-SCT recipients

演題番号 : OS-1-25

池邉 太一 (Taichi Ikebe):1,2、佐藤 隆子 (Takako Sato):1、中路 啓太 (Keita Nakaji):1、奥廣 和樹 (Kazuki Okuhiro):1、本田 周平 (Syuhei Honda):1、諸鹿 柚衣 (Yui Moroga):1、幸野 和洋 (Kazuhiro Kohno):1、緒方 正男 (Masao Ogata):1、門田 淳一 (Junichi Kadota):1、白尾 國昭 (Kuniaki Shirao):1

1:Department of Medical Oncology and Hematology Oita University、2:Department of Hematology, Oita Prefectural Hospital

 

Background: Treatment related mortality (TRM) after allogeneic stem cell transplantation (allo-SCT) remains high. Reliable biomarkers to predict prognosis or TRM of allo-SCT patients have yet to be identified.Aims: This study investigated whether tumor necrosis factor alpha receptor-1 (TNFα RI) and soluble interleukin-2 receptor (sIL-2R), and Leucine-rich alpha 2 glycoprotein (LRG) predict TRM in allo-SCT recipients.Methods: A total of 37 patients who underwent allo-SCT were enrolled. Plasma biomarkers were measured by sandwich ELISA in samples obtained weekly (n=279). Prognosis was compared between patients who had high (>median) and low (

前へ戻る